Abstract
Deficiency of iron is one of the most common nutritional disorders in the society. Iron deficiency anemia is described as decreased production in red blood cells (RBCs) due to low body iron stores.Anemia commonly occurs in people with chronic kidney disease and it might begin to develop in the early stages and tends to worsen as disease progresses. Iron supplementation is mandatory in the majority of patients with renal disease, particularly in those receiving ESA therapy. Treatment with intravenous iron in some clinical situations could present some advantages over oral iron, such as faster and higher increases of hemoglobin (Hb) levels and body iron stores. Some modern formulations of intravenous iron have emerged as a safe and effective alternative for iron deficiency anaemia management. E.g.: iron sucrose. Ferric carboxy maltose is a parenteral iron dextran-free product and the first of the new agents approved for rapid and high-dose replenishment of depleted iron stores.
 Keywords: Iron deficiency anaemia, chronic kidney disease, hemoglobin, iron sucrose, ferric carboxy maltose
Highlights
Deficiency of iron is one of the most common nutritional disorders in the society
Iron deficiency anemia is described as decreased production in red blood cells (RBCs) due to low body iron stores
Anemia commonly occurs in people with chronic kidney disease (CKD)-the permanent, partial loss of kidney function, it might begin to develop in the early stages of CKD and it tends to worsen as the disease progresses
Summary
Deficiency of iron is one of the most common nutritional disorders in the society. Iron deficiency anemia is described as decreased production in red blood cells (RBCs) due to low body iron stores. Most people who have total loss of kidney function, or kidney failure, have anemia.(2) IDA is common in chronic kidney disease (CKD) patients because of impaired intestinal absorption of dietary iron, blood loss, chronic inflammation, and increased iron requirements during therapy with erythropoiesis-stimulating agents (ESAs). A prevalent complication of CKD, IDA remains underdiagnosed and under treated Both early-stage CKD and anemia can be asymptomatic, so renal and hematologic laboratory values should be monitored annually in at-risk patients. Current intravenous iron formulations include high or low molecular weight iron dextran, ferric gluconate, iron sucrose and, very recently, ferric carboxymaltose (5). They all share the same structure, but differ from each other by the size of the core and the identity and density of the surrounding carbohydrate. FCM is cost effective and requires less frequent hospital visits which improve patient compliance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
